Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618267 | 1.00 | DGAT1 (0.38) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL27467334 | 0.85 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3285480 | 0.82 | FDPS (0.35) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL5187707 | 0.82 | FDPS (0.35) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL5488672 | 0.81 | CTSK (0.50) | CTSK | |
| SCHEMBL6706680 | 0.79 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL28714306 | 0.75 | DGAT1 (0.40) | DGAT1CTSK | |
| SCHEMBL14485423 | 0.74 | DGAT1 (0.48) | DGAT1MAOAMAOB | |
| SCHEMBL1433036 | 0.74 | DGAT1 (0.43) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL14485421 | 0.74 | DGAT1 (0.48) | DGAT1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| CN-1938323-A | Silinane compounds as cysteine protease inhibitors | SCHERING AG (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-7101880-B2 | Peptidic compounds as cysteine protease inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-7091360-B2 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMA S.A. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1495007-A4 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1495007-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AXYS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003087068-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | DGAT1 1951/4885CTSK 12/4885MAOA 1019/4885 |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | DGAT1 3444/4885CTSK 4/4885MAOA 1576/4885 |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | DGAT1 1951/4885CTSK 12/4885MAOA 1019/4885 |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | DGAT1 4431/4885CTSK 8/4885MAOA 2142/4885 |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | DGAT1 2220/4885CTSK 7/4885MAOA 1743/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | DGAT1 4611/4885CTSK 7/4885MAOA 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.